PE20120906A1 - Anticuerpos humanizados especificos de la forma protofibrilar del peptido beta-amiloide - Google Patents
Anticuerpos humanizados especificos de la forma protofibrilar del peptido beta-amiloideInfo
- Publication number
- PE20120906A1 PE20120906A1 PE2011001949A PE2011001949A PE20120906A1 PE 20120906 A1 PE20120906 A1 PE 20120906A1 PE 2011001949 A PE2011001949 A PE 2011001949A PE 2011001949 A PE2011001949 A PE 2011001949A PE 20120906 A1 PE20120906 A1 PE 20120906A1
- Authority
- PE
- Peru
- Prior art keywords
- protofibrillary
- beta
- specific humanized
- humanized antibodies
- amyloid peptide
- Prior art date
Links
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
REFERIDA A UN ANTICUERPO HUMANIZADO ESPECIFICO DE LA FORMA PROTOFIBRILAR QUE SE UNE A LOS PEPTIDOS A-BETA AGREGADOS EN PLACAS SENILESCARACTERIZADO POR: A) UNA PARTE VARIABLE DE SU CADENA PESADA ESTA CODIFICADA POR UNA SECUENCIA QUE PRESENTA AL MENOS 80% DE IDENTIDAD CON UNA DE LS SECUENCIAS SEC ID Nº 5, 6, 27, 28; B) UNA PARTE VARIABLE DE SU CADENA LIGERA ESTA CODIFICADA POR UNA SECUENCIA QUE PRESENTA AL MENOS 80% DE IDENTIDAD CON UNA DE LAS SECUENCIAS SEC ID Nº: 7, 8, 23, 24. LA AFINIDAD DE LA FORMA PROTOFIBRILAR DEL PEPTIDO ABETA ES AL MENOS 100 VECES SUPERIOR AL SU AFINIDAD POR OTRAS FORMAS DE ESTE PEPTIDO. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE TRASTORNOS DEGENERATIVOS TAL COMO AL ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0953133A FR2945538B1 (fr) | 2009-05-12 | 2009-05-12 | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120906A1 true PE20120906A1 (es) | 2012-08-08 |
Family
ID=41591699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001949A PE20120906A1 (es) | 2009-05-12 | 2010-05-11 | Anticuerpos humanizados especificos de la forma protofibrilar del peptido beta-amiloide |
Country Status (41)
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20171292T1 (hr) | 2007-11-16 | 2017-12-15 | The Rockfeller University | Polipeptidi i konjugati klorotoksina i njihove uporabe |
| AR085302A1 (es) * | 2011-02-24 | 2013-09-18 | Sanofi Sa | Metodo de produccion de anticuerpos sialilados |
| JP2013159596A (ja) * | 2012-02-08 | 2013-08-19 | Nihon Univ | β−アミロイド前駆体タンパク質のマイクロ凝集体に特異的なモノクローナル抗体 |
| MX359794B (es) | 2013-03-15 | 2018-10-10 | Intrinsic Lifesciences Llc | Anticuerpos anti-hepcidina y usos de los mismos. |
| CA3090240A1 (en) | 2014-08-08 | 2016-02-11 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| NZ730186A (en) | 2014-09-22 | 2020-04-24 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| LT3280441T (lt) | 2015-04-07 | 2021-11-25 | Alector Llc | Anti-sortilino antikūnai ir jų naudojimo būdai |
| EP3307771A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
| WO2016201389A2 (en) | 2015-06-12 | 2016-12-15 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| WO2017013599A1 (en) | 2015-07-21 | 2017-01-26 | Bioarctic Neuroscience Ab | Method for treatment of traumatic brain injury targeting aggregated peptides |
| JP7525980B2 (ja) | 2015-08-28 | 2024-07-31 | アレクトル エルエルシー | 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法 |
| JP7725185B2 (ja) | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| US10800844B2 (en) | 2015-10-29 | 2020-10-13 | Alector Llc | Anti-Siglec-9 antibodies and methods of use thereof |
| JP7023853B2 (ja) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗ｔｒｅｍ１抗体及びその使用方法 |
| CN109996809A (zh) | 2016-11-14 | 2019-07-09 | 诺华股份有限公司 | 与促融合蛋白minion相关的组合物、方法和治疗用途 |
| EP3354278A1 (en) | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| WO2018213316A1 (en) | 2017-05-16 | 2018-11-22 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| PE20200148A1 (es) | 2017-08-03 | 2020-01-17 | Alector Llc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| CN117700548A (zh) | 2017-08-03 | 2024-03-15 | 艾利妥 | 抗cd33抗体及其使用方法 |
| CA3098710A1 (en) | 2018-05-25 | 2019-11-28 | Alector Llc | Anti-sirpa antibodies and methods of use thereof |
| UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| BR112020024919A2 (pt) | 2018-06-08 | 2021-03-09 | Alector Llc | Anticorpos, ácido nucleico, vetor, célula hospedeira, métodos de produção de um anticorpo e de prevenção, redução do risco ou tratamento de câncer e composição farmacêutica |
| EP4212210A1 (en) | 2018-07-13 | 2023-07-19 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| WO2020023920A1 (en) | 2018-07-27 | 2020-01-30 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| WO2020047374A1 (en) | 2018-08-31 | 2020-03-05 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
| UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
| CN116063505B (zh) | 2019-01-30 | 2024-05-03 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| TW202110878A (zh) | 2019-05-16 | 2021-03-16 | 法商賽諾菲公司 | 在神經系統中表現抗原結合蛋白 |
| CR20210687A (es) | 2019-06-25 | 2022-03-03 | Gilead Sciences Inc | PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO |
| WO2021035033A1 (en) * | 2019-08-20 | 2021-02-25 | The Curators Of The University Of Missouri | Amyloid-beta antibodies |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| AU2020403021A1 (en) | 2019-12-12 | 2022-06-23 | Alector Llc | Methods of use of anti-CD33 antibodies |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN116157416A (zh) | 2020-08-25 | 2023-05-23 | 吉利德科学公司 | 靶向hiv的多特异性抗原结合分子及其使用方法 |
| TW202406932A (zh) | 2020-10-22 | 2024-02-16 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| EP1309341A2 (en) | 2000-07-07 | 2003-05-14 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| AU2001291096A1 (en) * | 2000-09-15 | 2002-03-26 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| WO2005087177A2 (en) * | 2004-03-05 | 2005-09-22 | Ludwig Institute For Cancer Research | Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| CA2544692C (en) * | 2004-07-09 | 2014-04-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| KR20070040824A (ko) * | 2004-07-30 | 2007-04-17 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용방법 |
| ATE497508T1 (de) * | 2004-10-01 | 2011-02-15 | Max Planck Gesellschaft | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper |
| AU2006208226A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
| WO2007108755A1 (en) * | 2006-03-22 | 2007-09-27 | Gyros Patent Ab | Plex method |
| MY169492A (en) * | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
| ES2439490T3 (es) * | 2007-01-05 | 2014-01-23 | University Of Zurich | Anticuerpo anti-beta amiloide y usos del mismo |
| CN101675075B (zh) * | 2007-03-01 | 2014-06-18 | 西福根有限公司 | 重组抗表皮生长因子受体抗体组合物 |
| TR201807983T4 (tr) | 2007-08-29 | 2018-06-21 | Sanofi Sa | İnsanlaştırılmış anti-CXCR5 antikorları, deriveleri ve kullanımları. |
| HRP20171292T1 (hr) * | 2007-11-16 | 2017-12-15 | The Rockfeller University | Polipeptidi i konjugati klorotoksina i njihove uporabe |
| DK3211005T3 (da) * | 2008-07-08 | 2021-06-07 | Geneuro Sa | Terapeutisk anvendelse af specifik ligand i msrv-associerede sygdomme |
| US8961991B2 (en) * | 2009-03-10 | 2015-02-24 | Baylor Research Institute | Anti-CD40 targeted fusion proteins |
| CA2754764A1 (en) * | 2009-03-10 | 2010-09-16 | Baylor Research Institute | Antigen presenting cell targeted cancer vaccines |
| TWI508976B (zh) * | 2009-04-21 | 2015-11-21 | Univ Rockefeller | 對β－類澱粉蛋白之基原纖維形式具專一性之抗體 |
-
2009
- 2009-05-12 FR FR0953133A patent/FR2945538B1/fr not_active Expired - Fee Related
-
2010
- 2010-05-11 UA UAA201114656A patent/UA107574C2/ru unknown
- 2010-05-11 CA CA2761665A patent/CA2761665A1/fr not_active Abandoned
- 2010-05-11 AU AU2010247215A patent/AU2010247215B2/en not_active Ceased
- 2010-05-11 PE PE2011001949A patent/PE20120906A1/es active IP Right Grant
- 2010-05-11 SI SI201030968T patent/SI2430049T1/sl unknown
- 2010-05-11 PT PT151605383T patent/PT2977385T/pt unknown
- 2010-05-11 EA EA201171388A patent/EA028357B1/ru not_active IP Right Cessation
- 2010-05-11 ES ES10728743.5T patent/ES2542757T3/es active Active
- 2010-05-11 US US13/319,710 patent/US8614299B2/en not_active Expired - Fee Related
- 2010-05-11 CN CN201080030434.6A patent/CN102459336B/zh not_active Expired - Fee Related
- 2010-05-11 EP EP15160538.3A patent/EP2977385B1/fr not_active Not-in-force
- 2010-05-11 WO PCT/FR2010/050915 patent/WO2010130946A1/fr not_active Ceased
- 2010-05-11 DK DK10728743.5T patent/DK2430049T3/en active
- 2010-05-11 PT PT107287435T patent/PT2430049E/pt unknown
- 2010-05-11 KR KR1020117029577A patent/KR101783058B1/ko not_active Expired - Fee Related
- 2010-05-11 PL PL10728743T patent/PL2430049T3/pl unknown
- 2010-05-11 HU HUE15160538A patent/HUE036737T2/hu unknown
- 2010-05-11 MA MA34434A patent/MA33350B1/fr unknown
- 2010-05-11 SG SG2011085255A patent/SG176155A1/en unknown
- 2010-05-11 RS RS20150459A patent/RS54122B1/sr unknown
- 2010-05-11 JP JP2012510343A patent/JP2012526541A/ja active Pending
- 2010-05-11 TW TW105112498A patent/TWI583791B/zh not_active IP Right Cessation
- 2010-05-11 PL PL15160538T patent/PL2977385T3/pl unknown
- 2010-05-11 BR BRPI1012853-0A patent/BRPI1012853B1/pt not_active IP Right Cessation
- 2010-05-11 EP EP10728743.5A patent/EP2430049B1/fr active Active
- 2010-05-11 HR HRP20150776TT patent/HRP20150776T1/hr unknown
- 2010-05-11 NZ NZ596540A patent/NZ596540A/xx not_active IP Right Cessation
- 2010-05-11 LT LTEP15160538.3T patent/LT2977385T/lt unknown
- 2010-05-11 ES ES15160538.3T patent/ES2664409T3/es active Active
- 2010-05-11 MX MX2011012060A patent/MX2011012060A/es active IP Right Grant
- 2010-05-11 AR ARP100101602A patent/AR076670A1/es active IP Right Grant
- 2010-05-11 SI SI201031662T patent/SI2977385T1/en unknown
- 2010-05-11 EP EP16155574.3A patent/EP3050898B1/fr not_active Not-in-force
- 2010-05-11 MY MYPI2011005458A patent/MY159398A/en unknown
- 2010-05-11 DK DK15160538.3T patent/DK2977385T3/en active
- 2010-05-11 TW TW099115013A patent/TWI542360B/zh not_active IP Right Cessation
- 2010-05-12 UY UY0001032633A patent/UY32633A/es active IP Right Grant
-
2011
- 2011-11-08 GT GT201100283A patent/GT201100283A/es unknown
- 2011-11-08 CR CR20110585A patent/CR20110585A/es unknown
- 2011-11-09 IL IL216237A patent/IL216237B/en active IP Right Grant
- 2011-11-10 TN TNP2011000571A patent/TN2011000571A1/fr unknown
- 2011-11-11 ZA ZA2011/08301A patent/ZA201108301B/en unknown
- 2011-11-11 CO CO11153627A patent/CO6460745A2/es active IP Right Grant
- 2011-11-11 SV SV2011004058A patent/SV2011004058A/es active IP Right Grant
- 2011-11-11 NI NI201100195A patent/NI201100195A/es unknown
- 2011-11-11 EC EC2011011452A patent/ECSP11011452A/es unknown
- 2011-11-11 CL CL2011002831A patent/CL2011002831A1/es unknown
-
2013
- 2013-10-01 US US14/042,942 patent/US9382312B2/en not_active Expired - Fee Related
-
2015
- 2015-07-14 CY CY20151100622T patent/CY1116842T1/el unknown
- 2015-10-01 JP JP2015195617A patent/JP6310895B2/ja not_active Expired - Fee Related
-
2016
- 2016-06-02 US US15/171,708 patent/US10112991B2/en not_active Expired - Fee Related
-
2018
- 2018-03-27 CY CY20181100343T patent/CY1120413T1/el unknown
- 2018-03-27 HR HRP20180516TT patent/HRP20180516T1/hr unknown
- 2018-09-26 US US16/142,666 patent/US20190119365A1/en not_active Abandoned
- 2018-11-27 HR HRP20181985TT patent/HRP20181985T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120906A1 (es) | Anticuerpos humanizados especificos de la forma protofibrilar del peptido beta-amiloide | |
| ES2584956T3 (es) | Anticuerpos anti-CD40 y usos de los mismos | |
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| MX2018009498A (es) | Anticuerpos anti-tnf, composiciones, métodos y uso para el tratamiento o la prevención de la diabetes tipo 1. | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| EA201491215A1 (ru) | Несиалированные противовоспалительные полипептиды | |
| JP2018504907A5 (es) | ||
| SG10201807877TA (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| MX347829B (es) | Molécula fv de unión a antígeno multivalente. | |
| RU2021134101A (ru) | Модифицированная j-цепь | |
| PE20180502A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| EA033433B1 (ru) | Антитела к tau и их применение | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| AR075504A1 (es) | Moleculas de anticuerpos que tienen especificidad para el ox40 humano | |
| PE20061040A1 (es) | Anticuerpos antiamiloides humanizados | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| PE20150960A1 (es) | Inmunoglobulinas heterodimericas | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| MX356367B (es) | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. | |
| UA110358C2 (en) | Molecules of antibody binding il-17a and il-17f | |
| NZ586053A (en) | Anti-vegf antibody compositions and methods | |
| CU20170039A7 (es) | Método de purificación del anticuerpo humanizado 9e4 | |
| PH12012501744A1 (en) | Biparatopic abeta binding polypeptides | |
| NZ610091A (en) | Antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |